A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Sponsor: Bristol-Myers Squibb

Sponsor score: 60

ClinicalTrials ID:NCT03661320

This study evaluates the efficacy of adding nivolumab to gemcitabine/cisplatin chemotherapy in untreated muscle-invasive bladder cancer. Eligible participants must be fit for and agree to undergo radical cystectomy post-neoadjuvant therapy, with an ECOG status of 0 or 1. Interventions include nivolumab, gemcitabine, and cisplatin, administered in specified doses on designated days.

Patient Parameters

Program Overview

The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).

Eligibility Criteria

Inclusion Criteria

  • Participant must be deemed eligible for Radial Cystectomy (RC) by his/her oncologist and/or urologist, and must agree to undergo Radial Cystectomy (RC) after completion of neoadjuvant therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

Exclusion Criteria

  • Clinical evidence of positive lymph node(s) (LN) (≥ 10 mm in short axis) or metastatic bladder cancer
  • Prior systemic therapy, radiation therapy, or surgery for bladder cancer other than trans urethral resection of bladder tumor (TURBT) or biopsies is also not permitted

Locations

FACILITYZIPCITYSTATE
Local Institution - 002285711TucsonArizona
UC Davis Comprehensive Cancer Center95817SacramentoCalifornia
Local Institution - 002180120-4413LittletonColorado
Local Institution - 003632503PensacolaFlorida
Local Institution - 000433612TampaFlorida
Local Institution - 014430342AtlantaGeorgia
Local Institution - 000560637ChicagoIllinois
Local Institution - 000661615PeoriaIllinois
Local Institution - 018121044ColumbiaMaryland
Local Institution - 000902114BostonMassachusetts

Get This Program In Your Inbox

You can sign up and apply your patients for this program.